Phase 2 Haematological Malignancy Clinical Trials
14 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–14 of 14 trials
Recruiting
Phase 2
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Haematological MalignancyBlood CancerFungal Infection+1 more
The University of Queensland104 enrolled7 locationsNCT06510699
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaHaematological Malignancy
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital250 enrolled5 locationsNCT05159245
Recruiting
Phase 2Phase 3
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Haematological MalignancyHypogammaglobulinemia
Monash University300 enrolled7 locationsNCT05678621
Completed
Phase 2
Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial
Oligometastatic Neoplasia to the Lung (from any non-haematological malignancy)
Trans Tasman Radiation Oncology Group (TROG)90 enrolled16 locationsACTRN12613001157763
Not Yet Recruiting
Phase 2
A trial of donor-derived cytotoxic T lymphocytes stimulated with an adenoviral vector containing the pp65 gene to prevent reactivation of cytomegalovirus following allogeneic stem cell transplantation for haematological malignancy
Immunosuppression post stem cell transplant for haematological malignancy
Sydney West Area Health Service60 enrolled1 locationACTRN12607000224426
Withdrawn
Phase 2
Evaluation of engraftment kinetics following double unit umbilical cord blood transplantation in patients with life threatening haematological malignancy in whom stem cell transplant (SCT) offers the only prospect of cure.
High risk haematological malignancy
Australasian Leukaemia and Lymphoma Group20 enrolled1 locationACTRN12606000303549
Recruiting
Phase 2
Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.
Acute Graft Versus Host Disease following allogeneic peripheral blood stem cell transplant from am HLA identical sibling for a haematological malignancy.
A/Prof Geoff Hill47 enrolled1 locationACTRN12605000460606